Zobrazeno 1 - 7 of 7 pro vyhledávání: '"Douglas Cines"'
1
COVID-ARDS: A Vascular Endotype
Autor: Andrew Vaughan, John Reilly, Douglas Cines, Nuala Meyer, Nilam Mangalmurti
COVID-19, the pandemic caused by the SARS-CoV-2 coronavirus can progress to pneumonia and Acute Respiratory Distress Syndrome (ARDS), resulting in an extraordinary level of ICU utilization and considerable mortality. Several pathophysiological featur
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6cf685c81e7fc6b3527138b33bc80996
https://doi.org/10.31219/osf.io/ckdpe
Zobrazit plný text záznamu
2
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients
Autor: Steve Vucic, Jeffrey Dunn, Douglas Cines, Carlo Pozzilli, Arnonk Karni, Samuel Hunter, Eva Kubala Havrdova, Tetyana Nehrych, Thor Petersen, Xavier Montalban, Jack Antel, Douglas Arnold, Vasyl Orzheshkovskyi, Krzysztof Selmaj, Michael Panzara, David Snydman, Alasdair Coles
Publikováno v: Neurology
Giovannoni, G, Cohen, J A, Coles, A J, Hartung, H-P, Havrdova, E, Selmaj, K W, Margolin, D H, Lake, S L, Kaup, S M, Panzara, M A, Compston, D A S, CARE-MS II Investigators (Thor Petersen, member) & Petersen, T 2016, ' Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients ', Neurology, vol. 87, no. 19, pp. 1985-1992 . https://doi.org/10.1212/WNL.0000000000003319
OBJECTIVE: To characterize effects of alemtuzumab treatment on measures of disability improvement in patients with relapsing-remitting multiple sclerosis (RRMS) with inadequate response (≥1 relapse) to prior therapy. METHODS: Comparison of Alemtuzu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9ef76e43bf89befb14797cfea6693c2
https://lirias.kuleuven.be/handle/123456789/619641
Zobrazit plný text záznamu
3
Abstract 172: tPA Variant tPA-A296-299 Prevents Impairment of Cerebral Autoregulation After Stroke Through LRP Dependent Increase in cAMP and p38 MAPK
Autor: William Armstead, John Riley, Serge Yarovoi, Abd Al-Roof Higazi, Douglas Cines
Publikováno v: Stroke. 47
Introduction: The sole FDA approved treatment for acute stroke is tissue type plasminogen activator (tPA). However, its brief therapeutic window and post-treatment complications markedly constrain its use. The limited efficacy of tPA may be explained
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8effa446ba86c11e7597a6d0153a7073
https://doi.org/10.1161/str.47.suppl_1.172
Zobrazit plný text záznamu
6
Abstract 2579: tPA Contributes To Aggravation of Endothelin and Thromboxane Induced Cerebrovasoconstriction After Hypoxia/Ischemia Through Upregulation of ERK MAPK
Autor: William Armstead, Heather Kaczynski, John Riley, Douglas Cines, Abd Al-Roof Higazi
Publikováno v: Stroke. 43
Introduction: The sole FDA approved treatment for acute stroke is tissue type plasminogen activator (tPA). However, endogenous tPA is upregulated and potentiates impairment of pial artery dilation in response to hypotension after hypoxia/ischemia (H/
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5f25be1184a99f32b7e214f18b8831c6
https://doi.org/10.1161/str.43.suppl_1.a2579
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje